jRCT2071240028进行中（未招募）不适用
Phase 1 Clinical Study of JTV-261 -Single and Multiple Dose Study-
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 88
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Other
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 45age old under（—）
- 性别
- Male
入选标准
- •Healthy Japanese male aged from 20 to 45 years
- •A subject with a body mass index (BMI) of 18.5 to less than 25.0
排除标准
- •A subject who has serious medical history of or complications under treatment for the cerebral, liver, kidneys, heart, lungs, gastrointestinal system, hematological, endocrine system, metabolic system, or psychiatric disorders.
- •A subjcet who has a history of gastrointestinal surgery that could interfere with the absorption of the study drug.
- •A subject who has participated in this study and received the study drug administration.
- •A subject who, in the opinion of the Investigator, has impediments to participation in the study.
结局指标
主要结局
-
Safety, Pharmacokinetics
次要结局
未报告次要终点
研究者
相似试验
终止
3 期
Efficacy and Safety of JT001 (VV116) Compared With FavipiravirModerate to Severe COVID-19NCT05279235Shanghai Vinnerna Biosciences Co., Ltd.290
已完成
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy ParticipantsHealthyNCT03550950Janssen Research & Development, LLC48
已完成
1 期
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid TumorsSolid TumorMetastatic CancerAdvanced CancerNCT04678921I-Mab Biopharma US Limited16
终止
2 期
JT001 (VV116) for the Early Treatment of COVID-19Mild to Moderate COVID-19NCT05242042Shanghai JunTop Biosciences Co., LTD381
未知
1 期
Phase 1 Clinical Study of JTS-661 - Pharmacokinetic Study in Patients on HemodialysisJapanese patients with CKD on maintenance hemodialysisJPRN-jRCT2080223686JAPAN TABACCO INC.6